About the Company
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NAVB News
Navidea Biopharmaceuticals Inc NAVB
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Navidea Biopharmaceuticals, Inc (NAVB) stock forecast and price target
Find the latest Navidea Biopharmaceuticals, Inc NAVB analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Navidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextran
Discover Navidea Biopharmaceuticals Inc's innovative method for conjugating metal chelating agents to dextran, free of crosslinking. Explore potential applications in medical imaging and drug delivery ...
Navidea Biopharmaceuticals files patent for polymeric compound for treating diseases involving macrophages
Discover how Navidea Biopharmaceuticals Inc. is revolutionizing targeted drug delivery with a patent for compounds to repolarize tumor-associated macrophages and treat cancer, autoimmune disorders, ...
Navidea chief medical officer steps down; hires G2G Ventures as consultants
Navidea Biopharmaceuticals (NYSE:NAVB) said Michael Rosol stepped down as chief medical officer and the company has hired G2G Ventures as executive consultants to help with its growth plans.
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics ...
Navidea Biopharmaceutical Stock (OTC:NAVB) Insider Trades
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...
William J. Regan's Net Worth
Who is William J. Regan? William J. Regan does not have any significant net worth to report based on the numbers we have. This is based on reported shares in NAVIDEA BIOPHARMACEUTICALS, INC..
NAVB Navidea Biopharmaceuticals, Inc.
The security has traded for less than one year There is no Wall Street analyst coverage The security is a closed-end fund or a mortgage REIT The security is listed on a non-US exchange The ...
Navidea Biopharmaceuticals Inc NAVB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Navidea Biopharmaceuticals, Inc. (NAVB)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Navidea Biopharmaceuticals, Inc. (NAVB)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...